Business, energy, technology, markets and global industry news from Business News Today

Pharma & Biotech

PharmaDeviceNews Pharma & Biotech
Representative image of a clinical weight-management consultation with an injection pen and progress chart, reflecting Pfizer’s berobenatide Phase 2b data and the growing race to develop monthly GLP-1 obesity treatments.
Pharma & Biotech

Pfizer’s Phase 2b obesity data put monthly GLP-1 dosing back in investor focus

Find out how Pfizer’s berobenatide Phase 2b data could reshape monthly GLP-1 obesity treatment and late-stage trial strategy.

Read More
Representative image of clinical diabetes data review, highlighting Corcept’s Korlym findings in hypercortisolism-linked type 2 diabetes and GLP-1 treatment outcomes.
Pharma & Biotech

Corcept’s Korlym data put hypercortisolism back in focus for cardiometabolic disease

Read how Corcept’s ADA data could reshape hypercortisolism screening in difficult-to-control type 2 diabetes and GLP-1 care.

Read More
Pharma & Biotech

Why MAIA Biotechnology’s ateganosine program is entering a decisive lung cancer development phase

Find out how MAIA Biotechnology’s ateganosine trials could shape the next phase of lung cancer drug development today.

Read More
Pharma & Biotech

Why Afrezza’s pediatric FDA approval could reshape mealtime insulin use in children with diabetes

Find out how Afrezza’s pediatric FDA approval could change mealtime insulin use for children with diabetes and MannKind’s growth story.

Read More
Representative image: A neurology consultation scene highlights the growing clinical focus on migraine prevention as Lundbeck’s bocunebart Phase IIb data strengthen interest in PACAP-targeted therapies for patients with hard-to-treat migraine.
Pharma & Biotech

Why Lundbeck’s anti-PACAP migraine drug could matter beyond another Phase II win

Find out how Lundbeck’s bocunebart Phase IIb data could reshape migraine prevention and test the PACAP pathway.

Read More
Crenessity two-year data highlight growing interest in long-term congenital adrenal hyperplasia treatment, steroid reduction, and endocrine outcomes. Representative image.
Pharma & Biotech

Neurocrine builds long-term case for Crenessity in congenital adrenal hyperplasia

See how Neurocrine’s two-year Crenessity data may reshape long-term classic CAH care, steroid reduction and pediatric outcomes.

Read More
Pharma & Biotech

Why Tempus’ tumor-only xT CDx approval could matter for precision oncology testing

Find out how Tempus’ tumor-only xT CDx FDA approval could expand precision oncology testing and reshape solid tumor profiling.

Read More
Pharma & Biotech

How Pharming’s Joenja resubmission could reopen the FDA pathway for pediatric APDS treatment

Find out how Pharming’s Joenja sNDA resubmission could reopen the FDA pathway for younger children with APDS.

Read More
Pharma & Biotech

Can L’Oréal-backed funding help OliX Pharmaceuticals turn siRNA science into a broader biotech platform?

Find out how OliX Pharmaceuticals’ KRW 110 billion raise could reshape RNAi therapeutics, beauty biotech, and siRNA platform strategy.

Read More
Representative image of a modern connected healthcare clinic, illustrating Semble’s £30 million funding round and its push to expand digital health software across Europe.
Pharma & Biotech

Why Semble’s £30m Series C could reshape private healthcare software in Europe

Find out how Semble’s £30M Series C could reshape connected healthcare software and private clinic workflows across Europe.

Read More